zonisamide has been researched along with MPTP Neurotoxicity Syndrome in 5 studies
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Zonisamide has been reported to have protective effects on epilepsy and Parkinson׳s disease and to work via various mechanisms of action, such as inhibition of monoamine oxidase-B and enhancement of tyrosine hydroxylase." | 1.42 | Zonisamide suppresses endoplasmic reticulum stress-induced neuronal cell damage in vitro and in vivo. ( Hara, H; Hashizume, T; Ishisaka, M; Shimazawa, M; Tsujii, S, 2015) |
| "Zonisamide is an antiepileptic drug that also improves the cardinal symptoms of Parkinson's disease." | 1.37 | Zonisamide-induced long-lasting recovery of dopaminergic neurons from MPTP-toxicity. ( Choudhury, ME; Kubo, M; Kyaw, WT; Matsuda, S; Moritoyo, T; Nagai, M; Nishikawa, N; Nomoto, M; Yabe, H, 2011) |
| "Zonisamide treatment alone did not produce any lasting effects on ex vivo MAO-B activity, indicating that it is a reversible inhibitor of the enzyme." | 1.36 | The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. ( Buckley, B; Sonsalla, PK; Winnik, B; Wong, LY, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsujii, S | 1 |
| Ishisaka, M | 1 |
| Shimazawa, M | 1 |
| Hashizume, T | 1 |
| Hara, H | 1 |
| Yano, R | 1 |
| Yokoyama, H | 1 |
| Kuroiwa, H | 1 |
| Kato, H | 1 |
| Araki, T | 1 |
| Sonsalla, PK | 1 |
| Wong, LY | 1 |
| Winnik, B | 1 |
| Buckley, B | 1 |
| Choudhury, ME | 2 |
| Moritoyo, T | 2 |
| Yabe, H | 2 |
| Nishikawa, N | 2 |
| Nagai, M | 2 |
| Kubo, M | 2 |
| Matsuda, S | 2 |
| Nomoto, M | 2 |
| Kyaw, WT | 1 |
5 other studies available for zonisamide and MPTP Neurotoxicity Syndrome
| Article | Year |
|---|---|
Zonisamide suppresses endoplasmic reticulum stress-induced neuronal cell damage in vitro and in vivo.
Topics: Animals; Anticonvulsants; Antiparkinson Agents; Cell Death; Cell Line, Tumor; Cell Survival; Disease | 2015 |
A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anticonvulsants; Antiparkinson Agents; Astroc | 2009 |
The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Antioxidants; Corpus Striatum; Diseas | 2010 |
Zonisamide attenuates MPTP neurotoxicity in marmosets.
Topics: Animals; Antiparkinson Agents; Callithrix; Corpus Striatum; Dopamine; Female; Humans; Isoxazoles; Ma | 2010 |
Zonisamide-induced long-lasting recovery of dopaminergic neurons from MPTP-toxicity.
Topics: Analysis of Variance; Animals; Antioxidants; Brain; Chromatography, High Pressure Liquid; Disease Mo | 2011 |